多发性骨髓瘤自体干细胞移植受者的微小残留病评估 - Suppr | 超能文献

相似文献

1

Minimal residual disease evaluation in autologous stem cell transplantation recipients with multiple myeloma.多发性骨髓瘤自体干细胞移植受者的微小残留病评估

Leuk Lymphoma. 2017 May;58(5):1234-1237. doi: 10.1080/10428194.2016.1228930. Epub 2016 Sep 23.

2

The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.多参数流式细胞术微小残留病评估在复发多发性骨髓瘤中的预后价值

Haematologica. 2015 Feb;100(2):e53-5. doi: 10.3324/haematol.2014.115162. Epub 2014 Nov 7.

3

A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center.

Leuk Lymphoma. 2018 Feb;59(2):515-518. doi: 10.1080/10428194.2017.1344906. Epub 2017 Jul 3.

4

Peripheral flow-MRD status at the time of autologous stem cell collection predicts outcome in multiple myeloma.自体干细胞采集时的外周血流微小残留病状态可预测多发性骨髓瘤的预后。

Bone Marrow Transplant. 2018 Dec;53(12):1599-1602. doi: 10.1038/s41409-018-0245-y. Epub 2018 Jun 8.

5

Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: a single center perspective.新型药物时代，大剂量美法仑联合自体干细胞支持治疗的多发性骨髓瘤中RAS突变状态对预后的有利影响：单中心观点

Leuk Lymphoma. 2016;57(1):226-9. doi: 10.3109/10428194.2015.1046863. Epub 2015 Jun 18.

6

Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient.更好的治疗需要更好的疗效评估：为每位骨髓瘤患者的微小残留病检测铺平道路。

Cytometry B Clin Cytom. 2016 Jan;90(1):14-20. doi: 10.1002/cyto.b.21273. Epub 2015 Dec 22.

7

Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen.骨髓瘤自体干细胞移植后的微小残留病：对预后的影响独立于诱导方案。

Haematologica. 2016 Feb;101(2):e69-71. doi: 10.3324/haematol.2015.128215. Epub 2015 Oct 15.

8

Digging deeper with allogeneic transplantation in multiple myeloma.深入探究多发性骨髓瘤的异基因移植

Biol Blood Marrow Transplant. 2013 Mar;19(3):335-6. doi: 10.1016/j.bbmt.2012.12.020. Epub 2013 Jan 2.

9

Long-term follow-up of tandem autologous stem-cell transplantation in multiple myeloma.多发性骨髓瘤串联自体干细胞移植的长期随访

J Clin Oncol. 2010 Dec 10;28(35):e741-3; author reply e744-5. doi: 10.1200/JCO.2010.31.5515. Epub 2010 Nov 8.

10

Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study.接受自体干细胞移植的多发性骨髓瘤患者的流式细胞术微小残留病监测：一项回顾性研究。

Leuk Lymphoma. 2008 Feb;49(2):306-14. doi: 10.1080/10428190701813018.

引用本文的文献

1

Advancing MRD Detection in Multiple Myeloma: Technologies, Applications, and Future Perspectives.多发性骨髓瘤中MRD检测的进展：技术、应用及未来展望

Am J Clin Oncol. 2025 Jul 1;48(7):376-380. doi: 10.1097/COC.0000000000001197. Epub 2025 Apr 11.

2

Prognostic Significance of the Stage at Which an MRD-Negative Status Is Achieved for Patients With Multiple Myeloma Who Received ASCT.接受自体造血干细胞移植（ASCT）的多发性骨髓瘤患者达到微小残留病（MRD）阴性状态时的分期的预后意义

Front Oncol. 2022 May 18;12:776920. doi: 10.3389/fonc.2022.776920. eCollection 2022.

3

Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study.